MOMETASONE FUROATE

Product Description

Mometasone Furoate API and Mometasone Furoate formulations. Niksan Pharmaceutical manufactures large quantity of Mometasone Furoate API  and finished products in Ankleshwar, Gujarat, India. Niksan Pharmaceutical and Niksan group companies are the largest manufacturers and suppliers of Mometasone Furoate API and products.

Niksan pharmaceutical is also large exporter of the API and finished pharmaceutical products of Mometasone Furoate in many countries for years. The countries where we exporting are Puerto Rico, Nepal, Oman, United Arab Emirates, Qatar, United States, Hong Kong, Singapore, Philippines, Sri Lanka, Indonesia, New Zealand,United Kingdom, Saudi Arabia, Kenya, Canada, Malaysia, Iraq, Pakistan,Australia, Taiwan, Vietnam, Ireland, Thailand, Germany, France and many more countries.

Niksan Pharmaceutical provides API and finished formulations of Mometasone Furoate in all over Indian states Like Kerala, Gujarat,Haryana, Rajasthan, Madhya Pradesh, Uttar Pradesh, Rajasthan, Karnataka,Meghalaya, Tamilnadu, Goa, Sikkim, Assam, Punjab, Delhi, Bihar, Jammu KashmirEtc. 

Mometasone Furoate is one type of medium strength corticosteroid.  Mometasone Furoate use in the skin condition,fever and also use in treatment of asthma. Mometasone Furoate use to treat some skin conditions like psoriasis, rashes, and allergies. 

IUPAC NAME:(1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-chloro-1-(2-chloroacetyl)-10-hydroxy-2,9a,11a-trimethyl-7-oxo-H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-ylfuran-2-carboxylate 

CAS NO: 83919-23-7 

FORMULA: C27H30Cl2O6 

MOLECULAR MASS: 427.36 g/mol 

STORAGE CONDITIONS: Store in cool and dry place.Place medicine away from direct heat and sun light. Do not put medicine in bathroom or kitchen. Keep away from children and pets 

HOW TO USE: Mometasone comes in the cream form for external use only, dot consume the medicine. Wash,clean and dry the part of skin before applying the cream. Do not use the cream on your face or in under arms or any open part of skin. 

HOW MOMETASONE WORKS: Mometasone Furoate also causes vasodilation of the smooth muscle and y this activity Mometasone Furoate used in the treatment of asthma.

PHARMACOKINETICS OF MOMETASONE FUROATE: Mometasone Furoate rapidly absorbed in the body after topical application. This drug takes 1-2.5 hours to reach the peak plasmaco ncentration. The bio availability of Mometasone  Furoate is <1%. Almost 98%-99% of drug binds with the plasma proteins. Half-life of the Mometasone Furoate is approximately 5 hours. Almost 74% of drug eliminated unchanged by faces and 8% of drug excreted by urination.

SIDE EFFECTS: The effects like burning, irritation, itching and swelling may occur after application o fthis medicine. The other side effects like acne, swelling of skin,discolouration of skin, unwanted hairs and stretch marks are also seen in some patients.Take advice of your doctor if side effects like weight loss, headache, vision problem, increase of urination seen in patients. 

PRECAUTIONS: Tell your doctor if you are allergic to the Mometasone Furoate. Tell your doctor if you have history like diabetes, weak immunity, poor blood circulation before taking medication. If you are already using the other medication tell your doctor about it. Take this medication in pregnancy or in lactation period whenstrictly needed.

CDSCO APPROVAL: Nadifloxacin (10mg/gm) +Mometasone Furoate (1mg/gm) cream approved by CDSCO in India in 17.08.2006,

Mometasone Furoate + Terbinafine HCl cream approved by CDSCO in India in 16.01.2002, 

Mometasone Furoate nasal spray 50 mcg/actuation(Additional Indication) approved by CDSCO in India in 21.05.2014,

Formoterol 6 mcg + Mometasone Furoate 100/200/400mcg Metered dose Inhaler & Dry Powder Inhalation approved by CDSCO in India in 30.12.2009,
Tazarotene (1mg) + Mometasone Furoate (1mg) per gram cream approved by CDSCO in India in 01.04.2005,

Mometasone Furoate approved by CDSCO in India in 1990- October,

Mometasone Furoate aqueous nasal spray approved by CDSCO in India in 18.05.2001,

Tazarotene (0.05%) + Mometasone Furoate (0.1%) Cream(addl.strength) approved by CDSCO in India in 24.05.2005,

Nadifloxacin (1%) + Miconazole Nitrate (2%) + Mometasone Furoate(0.1%) Cream approved by CDSCO in India in 06.06.2006.

FORMULATIONS AVAILABLE IN MARKET:

Nadifloxacin (10mg/gm) + Mometasone Furoate (1mg/gm) cream

Mometasone Furoate + Terbinafi ne HCl cream 

Mometasone Furoate nasal spray 50 mcg/actuation

Formoterol 6 mcg + Mometasone Furoate 100mcg Metered dose Inhaler

Formoterol 6 mcg + Mometasone Furoate 200mcg Metered dose Inhaler

Formoterol 6 mcg + Mometasone Furoate 400mcg Metered dose Inhaler

Tazarotene (1mg) + Mometasone Furoate (1mg) per gram cream

Mometasone Furoate aqueous nasal spray

Tazarotene (0.05%) + Mometasone Furoate (0.1%) Cream

Nadifloxacin (1%) + Miconazole Nitrate (2%) + Mometasone Furoate(0.1%) Cream

Note: Product protected by valid patents are not offered for sale in countries where such patents are still valid and its liability is at Buyers Risk

REFERENCES: 

www.webmd.com

https://pubchem.ncbi.nlm.nih.gov

https://go.drugbank.com

https://cdscoonline.gov.in

https://www.wikipedia.org

https://www.drugs.com

https://www.zaubacorp.com

https://www.practo.com/consult